Leber's hereditary optic neuropathy (LHON) is the most common mitochondrial disorder. Nuclear modifier genes are proposed to modify the phenotypic expression of LHON-associated mitochondrial DNA (mtDNA) mutations. By using an exome sequencing approach, we identified a LHON susceptibility allele (c. 572G>T, p.191Gly>Val) in YARS2 gene encoding mitochondrial tyrosyl-tRNA synthetase, which interacts with m.11778G>A mutation to cause visual failure. We performed functional assays by using lymphoblastoid cell lines derived from members of Chinese families (asymptomatic individuals carrying m.11778G>A mutation, or both m.11778G>A and heterozygous p.191Gly>Val mutations and symptomatic subjects harboring m.11778G>A and homozygous p.191Gly>Val mutations) and controls lacking these mutations. The 191Gly>Val mutation reduced the YARS2 protein level in the mutant cells. mutation worsened the respiratory phenotypes associated with m.11778G>A mutation, especially reducing activities of complexes I and IV. The respiratory deficiency altered the efficiency of mitochondrial ATP synthesis and increased the production of reactive oxygen species. Thus, mutated YARS2 aggravates mitochondrial dysfunctions associated with the m.11778G>A mutation, exceeding the threshold for the expression of blindness phenotype. Our findings provided new insights into the pathophysiology of LHON that were manifested by interaction between mtDNA mutation and mutated nuclear-modifier YARS2.
Introduction
Leber's hereditary optic neuropathy (LHON) [MIM53500] is the most common mitochondrial disorder leading to severe visual impairment or even blindness by death of retinal ganglion cells, affecting from children to young adults (1) (2) (3) (4) (5) . In the majority of cases worldwide, LHON is due to one of three point mutations in the mitochondrial DNA (mtDNA) encoding three subunits of respiratory chain complex I (NADH dehydrogenase): ND1 3460G>A, ND4 11778G>A and ND6 14684T>C mutations (5) (6) (7) (8) (9) (10) . Only ∼50% of male and ∼10% of female matrilineal relatives carrying one of above mutations develop optic neuropathy, reflecting the complex etiology of this disease (5, (11) (12) (13) . Furthermore, only relatively mild mitochondrial dysfunction, especially the reduced activity of complex I, was observed in mutant cells carrying one of these mutations (14) (15) (16) . These suggest that the LHON-associated mtDNA mutation (s) is the primary causative evident, but the additional genetic factors such as nuclear modifier genes are required for the phenotypic expression of LHON (5, (16) (17) (18) (19) . In particular, a predominance of male patients presenting with visual loss suggests a nuclear encoded Xlinked susceptibility allele(s) for the phenotypic manifestation of LHON-associated mtDNA mutations in some pedigrees (20) , while the inherited patterns of other families carrying the m.11778G>A or m.14484T>C mutation indicated the involvement of autosomal recessive modifier genes in the phenotypic expression (17, 19, 21, 22) .
Huge efforts have been undertaken in the last few years to identify LHON susceptibility alleles in the nuclear genomes. Despite statistical support for the linkages of several putative nuclear modifier loci, no mutations in these modifier genes have been identified (20, 21, 23) . Thus, the involvement of multiple factors and a relatively rare disorder make it very difficult to identify such nuclear modifier genes by use of conventional genetic approaches, such as genomewide linkage analysis. In this study, we used an exome sequencing approach, in combination with a functional cell assay, to identify the LHON susceptibility allele(s) in the nuclear genomes. By taking advantage of a large cohort of 1281 Chinese probands with LHON (24, 25) , we performed the exome sequencing of DNA from four members ( proband III-2, affected mother II-1 and unaffected sibling III-4 and father II-1) of WZ142 pedigree carrying the m.11778G>A mutation (26) . As a result, we identified a LHON susceptibility allele (c.572G>T, p.191Gly>Val) in YARS2 gene encoding mitochondrial tyrosyltRNA synthetase (27) . The change of highly conserved 191 residue glycine to valine at the catalytic domain may alter tRNA metabolism, thereby causing mitochondrial dysfunction (28) . We then performed Sanger sequence analysis of a cohort of 305 symptomatic subjects and 270 asymptomatic individuals of 167 Chinese pedigrees carrying m.11778G>A mutation and 265 controls subjects lacking the m.11778G>A mutation. Functional significance of the p.191G>V mutation in the YARS2 was first assessed for the effects on the stability of YARS2 and tRNA Tyr metabolism including aminoacylation capacities and stability of tRNA, through use of lymphoblastoid mutant cell lines derived from six matrilineal relatives of Chinese families (individuals carrying only the m.11778G>A mutation, or both m.11778G>A and heterozygous p.191Gly>Val mutations but lacking a clinical phenotype, and subjects exhibiting visual loss and both m.11778G>A and homozygous p.191Gly>Val mutations) and genetically unrelated control subjects lacking these mutations. This p.191Gly>Val mutation was further evaluated for effect on mitochondrial translation, respiration, production of ATP and reactive oxygen species (ROS) using above cell lines.
Results

Identification of YARS2 mutation by whole exome sequencing
To identify the nuclear modifier gene for the phenotypic manifestation of LHON-associated mtDNA mutation, we performed exome sequencing of DNA from four members ( proband III-I, affected mother II-2 and unaffected sibling III-4 and father II-1) of WZ142 family carrying the m.11778G>A mutation (Fig. 1A) . The overview of the exome analysis is summarized in Figure 1B and Supplementary Material, Table S1 . A total of 77 358 single nucleotide variants (SNVs) were identified as a result of variant calling. Of these, we excluded non-coding variants and then filtered for variants that were absent or present in less than 1% frequency in the 1000 genomes database, resulting in 3451 SNVs. Of these, 152 SNVs were homozygous and 2157 SNVs were heterozygous in proband III-I. Using the SIFT genome tool (http://sift.jcvi.org/www/SIFT_chr_coords_submit.html), seven of the homozygous SNVs were predicted to cause amino acid changes that would be damaging to the protein; and of the heterozygous SNVs, 21 genes were found to contain two or more variants predicted to be damaging. Using the MitoCarta database program for filtering these candidate genes, only one encoded a protein with a known mitochondrial function: YARS2 encoded the mitochondrial tyrosyl-tRNA synthetase (27) . The identified SNV c.572G>T is located in the exon I of YARS2 (RefSeq NC_000012.12) and results in the change of highly conserved 191 glycine to valine ( p.191Gly>Val) at the catalytic domain (28) . Sanger sequence analysis of DNA fragment spanning all exons and their flanking sequences of YARS2 (Fig. 1C) confirmed that symptomatic subjects II-2, III-1 carried the homozygous p.191Gly>Val mutation and asymptomatic individual III-4 and married-in-control II-1 harbored the heterozygous p.191Gly>Val mutation, respectively. Furthermore, we identified additional eight polymorphisms in these subjects (Supplementary Material, Table S2 ). We further analyzed the presence of the c.572G>T mutation in a cohort of 305 (212 male and 93 female) symptomatic and 270 asymptomatic subjects from 167 Chinese pedigrees carrying m.11778G>A mutation and 285 Chinese control subjects, by restriction fragment length polymorphism (RFLP) analysis, since the c.572G>T mutation disrupted a Tsp45I site, as shown in Figure 1D . Of 305 symptomatic subjects, 5 (3 male and 2 female) subjects who belonged to 4 pedigrees, as shown in Figure 1A , were homozygous for the c.572G>T mutation, 74 (48 male and 26 female) individuals were heterozygous for the c.572G>T mutation and the others lacked this mutation. In particular, six (2 male and 4 female) symptomatic individuals in the pedigree WZ1011 carried two subjects with homozygous mutation (two subjects), heterozygous mutation (three subjects) and lacked the mutation (one subject). However, homozygous c.572G>T mutation was not detected in all asymptomatic individuals and control individuals, while 49 asymptomatic individuals and 32 control subjects carried the heterozygous c.572G>T mutation. This translates to ∼28.7 and 18.5% frequency of this variant in the symptomatic subjects and asymptomatic subjects in this cohorts, respectively. Furthermore, 11.5% in the Chinese control subjects carrying this c.572G>T mutation was comparable with that of 12.66% in 1000 genome database (http://www.ncbi.nlm.nih.gov/projects/SNP/ snp_ref.cgi?rs=11539445). The co-segregation of LHON phenotype with the presence of homozygous c.572G>T and m.11778G>A mutations and higher incidence of this c.572G>T variant in these symptomatic subjects indicates that this variant is a LHON susceptibility allele.
To further investigate the role of mitochondrial variants in the phenotypic manifestation of m.11778G>A mutations in five families carrying homozygous c.572G>T mutation, we examined sequence analysis of entire mtDNA. As shown in Supplementary Material, Table S3 , there were no functional significant variants in these mtDNA genomes. These suggested that other mtDNA variants may not play an important role in the phenotypic manifestation of m.11778G>A mutation.
The p.191Gly>Val mutation causes the instability of YARS2
Human YARS2 comprises 477-amino acid protein containing a 16-amino acid mitochondrial targeting signal and catalytic site motifs characteristic of aminoacyl-tRNA synthetases (27) . The mutated residue G191 locates within the catalytic domain and is highly conserved among vertebrates ( Fig. 2A) . The protein prediction program SIFT (http://sift.jcvi.org) predicts the change of Gly191 to Asp or Val to be deleterious effect. As shown in Figure 2B , the Gly191 together with Gly190 form a Gly-Gly motif, located at the c-terminal end of a short α-helix of this protein (28) . The Gly190-Gly191 motif, same as other Gly-Gly motifs exhibiting a strong propensity to terminate an α-helical structure, may play an important role in maintaining the structural scaffold of YARS2. Thus, the p.191Gly>Val mutation could affect the structure and stability of the molecule. Furthermore, the Gly191 localizes at the interface between two YARS2 molecules in its dimeric form necessary for the function. The change of small Gly191 residue with the much bulkier Val could alter the association between two molecules of YARS2 in the dimer form.
To experimentally test the predicted effect of p.191Gly>Val mutation for YARS2, we analyzed the levels of YARS2 protein by western blotting in these mutant cell lines carrying only m.11778G>A mutation, both m.11778G>A and heterozygous or homozygous YARS2 p.191Gly>Val mutations and two control cell lines (Fig. 2C) . In general, the levels of YARS2 in cell lines carrying only m.11778G>A, both m.11778G>A and heterozygous or homozygous YARS2 p.191Gly>Val mutations were 107.8, 76.4 and 50.8%, relative to the average control values. These results strongly support a deleterious effect of p.191Gly>Val mutation on YARS2 structure. However, this mutation did not affect the subcellular location of YARS2 (Supplementary Material, Fig. S1 ). in control and mutant cell lines were examined by the use of electrophoresis in an acid polyacrylamide/urea gel system to separate uncharged tRNA species from the corresponding charged tRNA, electroblotting and hybridizing with above tRNA probes (29, 30) . As shown in Figure 3 , the upper band represented the charged tRNA, and the lower band was uncharged tRNA. Electrophoretic patterns showed no obvious differences in electrophoretic mobility of these tRNAs between control and mutant cell lines. Notably, the efficiencies of aminoacylated tRNA Tyr in these mutant cell lines carrying only m.11778G>A mutation, both m.11778G>A and heterozygous or homozygous c.572G>T mutations were 87.12% (P = 0.07), 75.4% (P = 0.01) and 56.7% (P = 0. Figure 4A , the levels of tRNA Tyr in mutant cells carrying both m.11778G>A and heterozygous or homozygous YARS2 c.572G>T mutations were markedly decreased, as compared with those in control cells. For comparison, the average level of each tRNA in control or mutant cell lines was normalized to the average levels in the same cell line for reference 5S RNA (31) . As shown in Figure 4B , the average steady-state levels of tRNA Tyr in mutant cell lines carrying only m.11778G>A mutation, both m.11778G>A and heterozygous or homozygous c.572G>T mutations were 92.5% (P = 0.14), 68.5% (P = 0.004) and 44.3% (P = 0.01) of control cell lines after normalization to 5S RNA, respectively. However, the average steady-state levels of tRNA 
Reduction in the level of mitochondrial proteins
To determine whether a failure in tRNA metabolism impaired mitochondrial translation, a western blot analysis was carried out to examine the steady-state levels of seven respiratory complex subunits in mutant and control cells with Tom20 (a nuclear gene encoding mitochondrial protein) as a loading control. As shown in Figure 5 , the levels of MT-CO2, subunit 2 of cytochrome c oxidase; MT-ND1, MT-ND4, MT-ND5 and MT-ND6, subunits 1, 4, 5 and 6 of NADH dehydrogenase; MT-CYTB, apocytochrome b; MT-ATP6 and subunit 6 of the H + -ATPase were decreased in mutant cell lines, as compared with those of control cell lines. As shown in Figure 5B , the overall levels of seven mitochondrial translation products in the mutant cell carrying only m.11778G>A mutation, both m.11778G>A and heterozygous or homozygous c.572G>T mutations were 115.8% (P = 0.14), 56.4% (P = 0.004) and 35.6% (P = 0.01) of two control cell lines, respectively. Notably, the average levels of MT-ND1, MT-ND4, MT-ND5, MT-ND6, MT-ATP6, MT-CO2 and MT-CYTB in the mutant cells carrying both m.11778G>A and homozygous c.572G>T mutations were 16.9, 27, 40. However, the average levels of these polypeptides in the mutant cells carrying only m.11778G>A mutations were comparable to those of control cells.
Reduced activity of complexes I and IV
To investigate the effect of the YARS2 c.572G>T mutation on the oxidative phosphorylation, we measured the activities of respiratory complexes by isolating mitochondria from mutant and control cell lines. Complex I (NADH ubiquinone oxidoreductase) activity was determined by following the oxidation of NADH with ubiquinone as the electron acceptor (32,33). Complex III (ubiquinone cytochrome c oxidoreductase) activity was measured as the reduction of cytochrome c (III) using -ubiquinol-2 as the electron donor. The activity of complex IV (cytochrome c oxidase) was monitored by following the oxidation of cytochrome c (II). As shown in Figure 6 , the activity of complex I in the mutant cell carrying only 11778G>A mutation, both m.11778G>A and heterozygous or homozygous c.572G>T mutations were 92.4, 75 and 51.4% of two control cell lines, respectively. Notably, the activity of complex IV in the mutant cell carrying only m.11778G>A mutation, both m.11778G>A and heterozygous or homozygous c.572G>T mutations were 108.8, 75 and 38.2% of two control cell lines, respectively. However, the activities of and MT-CYTB in six mutant cell lines and two control cell lines were determined as described elsewhere (30) .
complexes II and III in all mutant cell lines were comparable with those of control cell lines.
Respiration defects
To evaluate if the YARS2 c.572G>T mutation alters cellular bioenergetics, we examined the oxygen consumption rates (OCR) of mutant and control cells lines (34) . As shown in Figure 7 , the basal OCR in the mutant cell lines carrying only m.11778G>A or both m.11778G>A with homozygous or heterozygous c.572G>T mutations was 106.6, 95.6 and 63.1% relative to the mean value measured in the control cell lines, respectively. To investigate which of the enzyme complexes of the respiratory chain was affected in the mutant cell lines, OCR were measured after the sequential addition of oligomycin (inhibit the ATP synthase), FCCP (to uncouple the mitochondrial inner membrane and allow for maximum electron flux through the ETC), rotenone (to inhibit complex I) and antimycin (to inhibit complex III) (complex V). The difference between the basal OCR and the drug-insensitive OCR yields the amount of ATP-linked OCR, proton leak OCR, maximal OCR, reserve capacity and non-mitochondrial OCR. As shown in Figure 7 , the ATP-linked OCR, proton leak OCR, maximal OCR, reserve capacity and non-mitochondrial OCR in mutant cell lines carrying the m.11778G>A with homozygous c.572G>T mutations were 51. 
Reduced level in mitochondrial ATP production
The capacity of oxidative phosphorylation in mutant and wildtype cells was examined by measuring the levels of cellular and mitochondrial ATP production using a luciferin/luciferase assay. Populations of cells were incubated in the media in the presence of glucose (reflects total cellular ATP production), or 2-deoxy--glucose with pyruvate (reflects mitochondrial ATP production) (35) (36) . In the presence of glucose, the levels of total cellular ATP production in mutant cells were comparable with those measured in the control cell lines (data now shown). In the presence of pyruvate and 2-deoxy--glucose to inhibit the glycolysis, the levels of mitochondrial ATP production in the mutant cell lines harboring only m.11778G>A mutation, both m.11778G>A and heterozygous or homozygous YARS2 c.572G>T mutations were 80.2% (P = 0.10), 71.6% (P = 0.04) and 49% (P = 0.018) of average value of two control cell lines (Fig. 8A ).
The increase of ROS production
The levels of the ROS generation in the vital cells derived from control and mutant cell lines were measured with flow cytometry under normal and H 2 O 2 stimulation (36,37). Geometric mean intensity was recorded to measure the rate of ROS of each sample. The ratio of geometric mean intensity between unstimulated and stimulated with H 2 O 2 in each cell line was calculated to delineate the reaction upon increasing level of ROS under oxidative stress. As shown in Figure 8B , the levels of ROS generation in the mutant cell lines carrying only m.11778G>A mutation, both m.11778G>A and heterozygous or homozygous YARS2 c.572G>T mutations were 111.5% (P = 0.30), 114.8% (P = 0.07) and 147.2% (P = 0.015) of two control cell lines.
Discussion
Nuclear modifier genes were proposed to increase the susceptibility to LHON-associated mtDNA mutations (38, 39 . However, these reduced levels of tRNA Tyr in mutant cells were indeed above the proposed threshold level (>70% reduction) to produce a clinical phenotype associated with tRNA mutations (43, 44) . This suggested that the YARS2 p.191Gly>Val mutation is by itself insufficient to produce a clinical phenotype, as in the case of the nuclear modifier TRMU p.10Ala>-Ser mutation for deafness-associated 12S rRNA 1555A>G mutation (31) . A failure in the tRNA Tyr metabolism caused by the YARS2 p.191Gly>Val mutation then affects mitochondrial protein synthesis. In fact, the mtDNA encoded 13 polypeptides in the complexes of the oxidative phosphorylation system (MT-ND1-6, ND4L of complex I, MT-CYTB of complex III, MT-CO1, CO2, CO3 of complex IV, and MT-ATP6 and MT-ATP8 of complex V) (45, 46) . In this study, 39 and 61% reductions in the levels of mitochondrial proteins were observed in mutant cell lines carrying both m.11778G>A and heterozygous or homozygous YARS2 p.191Gly>Val mutations, respectively. These results were comparable with those in cell lines carrying YARS2 p.52Phe>Leu or p.49Gly>Asp mutation (45, 46) . Notably, variable decreases in the levels of seven mtDNA-encoded polypeptides were observed Table S4 , cell lines carrying both m.11778G>A and homozygous YARS2 p.191Gly>Val mutations exhibited marked reductions (59 to 83%) in the levels of five polypeptides (MT-ND1, MT-ND4, MT-ND5, MT-ND6 and MT-CO2) harboring 9-16 tyrosine codons, a relative mild reduction (23%) in the level of MT-CYTB carrying 17 tyrosine codons, but a mild increased level (5%) in the level of MT-ATP6 with only three tyrosine codons. In the other studies, the in vivo Pulse-labeling mitochondrial protein synthesis assay also showed much less reductions in the levels of MT-ND3, MT-ND4L, MT-ATP6 and MT-ATP8 than those of other polypeptides with high tyrosine codons in mutant cell lines carrying the YARS2 p.52Phe>Leu and p.49Gly>Asp mutations (47, 48) . However, these data were not fully comparable with the case of MERRF-associated m.8344A>G mutation in tRNA Lys gene (49) .
Thus, the impaired synthesis of MT-ND1, MT-ND4, MT-ND5 and MT-ND6, subunits of complex I and MT-CO1, MT-CO2 and MT-CO3, subunits of complex IV may alter the activities of complexes I and IV and then worsen the respiratory phenotypes associated with m.11778G>A mutation. In this study, 25 and 49.4% decreases of complex I activity, 25 and 62% reductions in complex IV activities were observed in cell lines harboring both m.11778G>A and heterozygous or homozygous YARS2 p.191Gly>Val mutations, while ∼10% decrease in the activity of complex I but not those of complexes III and IV in these mutant cell lines carrying only m.11778G>A mutation (14, 15) . Furthermore, alteration in mitochondrial protein synthesis was apparently responsible for the reduced rates in the basal OCR, or ATP-linked OCR, reserve capacity and maximal OCR among the control and mutant cell lines. In particular, the 37, 43 and 66% decreases in maximal OCR reduction were observed in cell lines harboring only m.11778G>A mutation, both m.11778G>A and heterozygous or homozygous YARS2 p.191Gly>Val mutations, respectively. This correlation is clearly consistent with the importance that a failure in tRNA metabolism plays a critical role in producing their respiration defects, as in the cases of cells carrying both TRMU 10Ala>Ser and deafness-associated 12S rRNA 1555A>G mutations (31) . The respiratory deficiency then affects the efficiency of mitochondrial ATP synthesis. In this investigation, 20% reduction of mitochondrial ATP production in lymphoblastoid cell lines carrying only m.111778G>A mutation may be caused by the defective activity of complex I, as in the cases of cybrid cell lines bearing the m.3460G>A, m.14484T>C or m.11778G>A mutations (50, 51) . In contrast, ∼51% drop in mitochondrial ATP production in lymphoblastoid cell lines bearing both m.11778G>A and homozygous YARS2 p.191Gly>Val mutations may result from the defective activities of Complexes I and IV. Indeed, our previous investigation implicated that marked decreases in mitochondrial ATP production in lymphoblastoid cell lines derived from a large Chinese pedigree with high penetrance of LHON resulted from altered activity of Complexes I and III (35) . The impairment of oxidative phosphorylation can lead to more electron leakage from electron transport chain, and in turn, elevate the production of ROS in mutant cells (52) . Here, the mildly reduced production of mitochondrial ATP in the lymphoblastoid cell lines carrying only m.11778G>A mutation was in a good agreement with the previous observation in cybrid cell lines harboring the same mutation (51, 53) . However, 47% increase of ROS production in cells carrying both m.11778G>A and homozygous YARS2 p.191Gly>Val mutations was the consequence of the altered activities of Complexes I and IV. The overproduction of ROS can establish a vicious cycle of oxidative stress in the mitochondria, thereby damaging mitochondrial and cellular proteins, lipids and nuclear acids (54) . The retinal ganglion cells may be preferentially involved because they are somehow exquisitely sensitive to subtle imbalance in cellular redox state or increased level of free radicals (54, 55) . This would lead to dysfunction or apoptosis of retinal ganglion cells carrying both m.11778G>A and p.191Gly>Val mutations, thereby producing a phenotype of visual loss (5, 56) .
In summary, our study has identified the first nuclear modifier gene YARS2 for the phenotypic expression of LHON-associated mtDNA mutations. The mutated YARS2 causes the inefficient aminoacylation and lower level of tRNA Tyr , subsequently impairing mitochondrial translation, specially for polypeptides with high content of tyrosine codon. Resultant biochemical defects aggravate the mitochondrial dysfunction associated with m.11778G>A mutation, below the threshold for normal cell function, thereby expressing the LHON phenotype. Therefore, the mutated YARS2, acting as a nuclear modifier, triggers the optic neuropathy in individuals harboring the m.11778G>A mutation. Thus, our findings provide new insights into the understanding of pathophysiology of not only mitochondrial disease such as LHON but also neurodegenerative diseases such as Parkinson's.
Materials and Methods
Families and subjects
DNA samples used for this investigation were from members of families who carried the m.11778G>A mutation: 307 symptomatic and 271 asymptomatic members from 167 Han Chinese pedigrees with LHON (19, 22, 25, 26) . A total of 285 control DNA samples lacking the m.11778G>A mutation were obtained from adult Han Chinese from same area. The ophthalmic examinations and other clinical evaluations of probands, other members of these families and 285 control subjects were conducted as detailed elsewhere (22, 25, 26) . Informed consent, blood samples and clinical evaluations were obtained from all participants and families, under protocols approved by the Institutional Review Board of Cincinnati Children's Hospital, Ethic Committees of Zhejiang University and the Wenzhou Medical University.
Whole exome sequencing
Whole exome sequencings of four subjects (III-1, III-4, II-2 and II-1) of WZ142 pedigree carrying the m.11778G>A mutation were performed by BGI (Shenzhen, China). High-quality genomic DNA (3 μg) was captured by hybridization using the SureSelect XT Human All Exon 50 Mb kit (Agilent Technologies). Samples were prepared according to the manufacturer's instructions. Each captured library was run on a HiSeq 2000 instrument and sequences generated as 90 bp pair-end reads. An average of 82 million paired reads was generated per sample, the mean duplication rate was 6.37, and 98% of the targeted region was covered by at least 50 × mean depth. All sequencing reads were mapped to the human reference genome (GRCh37) at UCSC. Software SOAPsnp was used to assemble the consensus sequence and call genotypes in target regions. GATK (Indel Genotyper V1.0) was used to indel detection. The threshold for filtering single-nucleotide polymorphisms (SNPs) included the following criterion: SNP quality score should be ≥20; sequencing depth should be between 4 and 200; estimated copy number should be no more than 2 and the distance between two SNPs should be larger than 5.
Mutation analysis of YARS2 gene
Five pairs of primers for PCR-amplifying exons and their flanking sequences, including splicing-donor and acceptor-consensus sequences of YARS2, were used for this analysis. The forward and reverse primers for PCR amplification and sequence analysis are shown in Supplementary Material, Table S5 . Fragments spanning five exons and flanking sequences from three matrilineal relatives (II-2, III-1 and III-4) and one spouse (II-1) of WZ142 pedigree, and two genetically unrelated Chinese controls were PCR amplified, purified and subsequently analyzed by direct sequencing in an ABI 3700 automated DNA sequencer with use of the Big Dye Terminator Cycle sequencing reaction kit (Applied Biosystems). These sequence results were compared with the YARS genomic sequence (RefSeq NC_000012.12). Genotyping for the c.572G>T mutation in other subjects was PCR amplified for exon 1 and followed by digestion of the 623-bp segment with the restriction enzyme Tsp45I. The forward and reverse primers for exon 1 are 5′-GA CTCGCTTCATGTGGGTCAT-3′ and 5′-CGAAGGGCAGCAACTAC AATC-3′, respectively. The Tsp45I-digested products were analyzed on 1.5% polyacrymide gel.
Sequence analysis of mitochondrial genomes
The entire mitochondrial genomes of five Chinese families carrying homozygous YARS2 c.572G>T and m.11778G>A mutations were analyzed as described elsewhere (57) . The resulting sequence data were compared with the updated consensus Cambridge sequence (GenBank accession number: NC_012920) (45) .
Cell lines and culture conditions
Lymphoblastoid cell lines were immortalized by transformation with the Epstein-Barr virus, as described previously (58) . Cell lines derived from two matrilineal members of WZ142 pedigree (III-1, III-4), four matrilineal members of WZ1011 and two genetically unrelated control individuals C1 and C2 were grown in RPMI 1640 medium (Invitrogen), supplemented with 10% fetal bovine serum.
Mitochondrial tRNA analysis
Mitochondria were isolated from various cell lines (∼2.0 × 10 8 cells), as described previously (59) . For the aminoacylation assays, total mitochondrial RNAs were isolated under acid conditions, and 2 μg of total mitochondrial RNAs was electrophoresed at 4°C through an acid ( pH 5.2) 10% polyacrylamide-7 M urea gel to separate the charged and uncharged tRNA as detailed elsewhere (29, 60) . For the tRNA Northern analysis, total mitochondrial RNAs were isolated using TOTALLY RNA™ kit (Ambion), as described previously, 2 μg of total mitochondrial RNA were electrophoresed through a 10% polyacrylamide/7 M urea gel in Trisborate-EDTA buffer (TBE) (after heating the sample at 65°C for 10 min). The gels were then electroblotted onto a positively charged nylon membrane (Roche) for the hybridization analysis with non-radioactive digoxin (DIG)-labeled oligodeoxynucleotide probes for tRNA , tRNA Ser(AGY) or 5S RNA, as detailed previously (30, 60, 61, 62) . DIG-labeled oligodeoxynucleotides were generated by using DIG oligonucleotide Tailing kit (Roche). The hybridization and quantification of density in each band were performed as detailed previously (30) .
Western blot analysis
Western blotting analysis was performed as detailed previously (30) . The antibodies used for this investigation were from Abcam [anti YARS2 (ab68725), TOM20 (ab56783), VDAC (ab14734), MT-ND1 (ab74257), MT-ND5 (ab92624) and MT-ATP6 (ab101908), MT-CO2 (ab110258)], Santa Cruz Biotechnology [MT-ND4
(sc-20499-R) and MT-ND6 (sc-20667)] and Proteintech [MT-CYTB (55090-1-AP)]. Peroxidase Affini Pure goat anti-mouse IgG and goat anti-rabbit IgG (Jackson) were used as a secondary antibody and protein signals were detected using the ECL system (CWBIO). Quantification of density in each band was performed as detailed previously (30) .
Measurements of oxygen consumption
The rates of oxygen consumption in cybrid cell lines were measured with a Seahorse Bioscience XF-96 extracellular flux analyzer (Seahorse Bioscience), as detailed previously (30, 34) .
Enzymatic assays
The enzymatic activities of complexes I, II, III and IV were assayed as detailed elsewhere (32, 33, 63) .
ATP measurements
The Cell Titer-Glo ® Luminescent Cell Viability Assay kit (Promega) was used for the measurement of cellular and mitochondrial ATP levels, according to the modified manufacturer's instructions (30, 35, 36) .
ROS measurements
ROS measurements were performed following the procedures detailed previously (35) (36) (37) .
Computer analysis
Statistical analysis was carried out using the unpaired, two-tailed Student's t-test contained in the Microsoft-Excel program or Macintosh (version 2007). Differences were considered significant at a P < 0.05.
Supplementary Material
Supplementary Material is available at HMG online.
